Fig. 1From: Nanoarchitectured conjugates targeting angiogenesis: investigating heparin-taurocholate acid conjugates (LHT7) as an advanced anti-angiogenic therapy for brain tumor treatmentAnti-proliferation effect of LHT7 on U87MG. a Cell viability of U87MG in the presence or absence of VEGF (10 μg/mL) and EGF (10 μg/mL), respectively. Data are expressed as mean ± SEM (n = 5). b Cell viability of U87MG with LHT7 treatment in the concentration range of 1–100 μg/mL. Data are expressed as mean ± SEM (n = 5). c VEGF concentration in U87MG cell lysate after 24 h treatment with LHT7 (100 μg/mL). Data are expressed as mean ± SEM (n = 5)Back to article page